loading page

Mechanism of αO-Conotoxin GeXIVA[1,2], a Novel Nonaddictive Analgesic, Based on In Vivo Disposition and Modelling
  • +4
  • Xiaoyu Zhu,
  • mei yuan,
  • Huanbai Wang,
  • dongting zhangsun,
  • Gang Yu,
  • Jijing Che,
  • Lan Su
Xiaoyu Zhu
Hainan University

Corresponding Author:[email protected]

Author Profile
mei yuan
Institute of Pharmacology and Toxicology
Author Profile
Huanbai Wang
Hainan University
Author Profile
dongting zhangsun
Hainan University
Author Profile
Gang Yu
Beijing Institute of Pharmacology and Toxicology
Author Profile
Jijing Che
Beijing Institute of Pharmacology and Toxicology
Author Profile
Lan Su
Hainan University
Author Profile

Abstract

Background and purpose: αO-conotoxin GeXIVA[1,2], a natural peptide discovered by our laboratory from Conus generalis in the South China Sea, is a novel nonaddictive analgesic targeting the α9α10 nicotinic acetylcholine receptor (nAChR). This study aimed to elucidate the underlying mechanisms by the disposition and modelling of GeXIVA[1,2]. Experimental approach: The pharmacokinetics (PK) of GeXIVA[1,2] and tissue distribution in rats and dogs were studied. A population pharmacokinetics model and a pharmacokinetic-pharmacodynamic model were developed based on animal data and used to predict the efficacious dose in humans and explain the mechanism. Key results: The intramuscular bioavailability of GeXIVA[1,2] was 11.47% and 13.37% in rats and dogs, respectively. Across experimental doses, the plasma exposure increased approximately in proportion to dose, and the half-life of GeXIVA[1,2] ranged from 5.37±0.99 to 19.65±6.21 min. GeXIVA[1,2] had less extensive tissue distribution. The bound fractions differed in human, rat, and dog plasma, ranging from 55.85±5.10% to 87.64±7.49%. The one-compartment model with the first-order absorption PPK model estimated an efficacious dose of 11.9-30.8 μg·kg-1 in a 70 kg human with bodyweight as a covariant. The inhibitory loss indirect response model combined with an effect compartment adequately described PK-PD relationships. Conclusion and implications: We speculated that GeXIVA[1,2] exerts analgesia by inhibiting the elimination of certain endogenous substances, which may be a key pharmacodynamic biomarker. This is the first report of the disposition of conotoxin-derived therapeutic agents and possible analgesic mechanisms of α9α10 nAChR, which were elucidated by PK studies and modelling approaches.